Когнитивный резерв и когнитивные нарушения: лекарственные и нелекарственные методы коррекции
https://doi.org/10.14412/2074-2711-2014-2S-62-68
Аннотация
В статье обсуждаются такие понятия, как когнитивный резерв (КР) и когнитивные нарушения (КН). Представлены управляемые и некорригируемые факторы, влияющие на состояние когнитивного резерва. Рассмотрены факторы повышения КР и снижения риска развития деменции. Освещены механизмы развития сосудистых КН и роль сосудистого фактора в возникновении нейродегенеративных заболеваний, в первую очередь болезни Альцгеймера и болезни Паркинсона. Обсуждаются вопросы коррекции КН при цереброваскулярной и нейродегенеративной патологии. Показано значение концепции КР для планирования тактики ведения каждого пациента с целью профилактики деменции с использованием лекарственных и нелекарственных методов.
Об авторах
Е.И. Дайникова
Кафедра неврологии и медицинской генетики с курсом нейрохирургии, ГБОУ ВПО «Ярославская государственная медицинская академия» Минздрава России, Ярославль; 150000, Ярославль, ул. Революционная, д. 5
Россия
Россия
Н.В. Пизова
Кафедра неврологии и медицинской генетики с курсом нейрохирургии, ГБОУ ВПО «Ярославская государственная медицинская академия» Минздрава России, Ярославль; 150000, Ярославль, ул. Революционная, д. 5
Россия
Россия
Список литературы
1. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsyhol Soc. 2002;8(3):448–60. DOI: http://dx.doi.org/10.1017/S1355617702813248.
2. Perneczky R, Alexopoulos P, Schmid G, еt al. Cognitive reserve and its relevance for the prevention and diagnosis of dementia. Nervenarzt. 2011;82(3):325–30,332–5. DOI: 10.1007/s00115-010-3165-7.
3. Stern Y. Exploring the neural basis of cognitive reserve. J Clin Exp Neuropsychol. 2003;25(5):691–701.
4. Sole-Padulles C, Bartres-Faz D, Junque C, et al. Brain structure and function related to cognitive reserve variables in normal aging, mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2009;30(7):1114–24.
5. Scarmeas N, Zarahn E, Anderson K, et al. Association of life activities with cerebral blood flow in Alzheimer disease: implications for the cognitive reserve hypothesis. Arch Neurol. 2003;60(3):359–65. DOI: http://dx.doi.org/10.1001/archneur.60.3.359. 6. Ghaffar N, Fiati M, Feinstein A. Occupational attainment as a marker of cognitive reserve in multiple sclerosis. PLoS. 2012;7(10):e47206. DOI: 10.1371/journal.pone.0047206. Epub 2012 Oct 5.
6. Adam S, Bonsang E, Grotz C, Perelman S. Occupational activity and cognitive reserve: implications in terms of prevention of cognitive aging and Alzheimer's disease. Clin Interv Aging. 2013;(8):377–90. DOI:
7. 2147/CIA.S39921. Epub 2013 Apr 11.
8. Bialystok E, Craik F, Klein R, Viswanathan M. Bilingualism, aging, and cognitive control: evidence from the Simon task. Psychol Aging. 2004;19(4):290–303. DOI: http://dx.doi.org/10.1037/0882-7974.19.2.290.
9. Bak TH, Nissan JJ, Allerhand MM, Deary IJ. Does bilingualism influence cognitive aging? Ann Neurol. 2014;75(6):959–63.
10. Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA. 2011;108(7):3017–22. DOI: 10.1073/pnas.1015950108. Epub 2011 Jan 31.
11. Abbott RD, White L, Ross GW, et al. Walking and Dementia in Physically Capable Elderly Men. JAMA. 2004;292(12):1447–53. DOI: http://dx.doi.org/10.1001/jama.292.12.1447.
12. Carmeas N, Levy G, Tang MX, et al. Influence of leisure activity on the incidence of Alzheimer's disease. Neurology. 2001;57(12):2236–42. DOI: http://dx.doi.org/10.1212/WNL.57.12.2236.
13. Weuve J, Kang JH, Manson JAE. Physical activity, including walking, and cognitive function in older women. JAMA.2004;292(12):1454–61. DOI: http://dx.doi.org/10.1001/jama.292.12.1454.
14. Teri L, Gibbons LE, McCurry SM. Exercise plus behavioral management in patients with alzheimer disease (a randomized controlled trial). JAMA. 2003 Oct 15;290(15):2015–22. DOI: http://dx.doi.org/10.1001/jama.290.15.2015.
15. Захаров ВВ, Яхно НН. Синдром умеренных когнитивных расстройств в пожилом возрасте: диагностика и лечение. Русский медицинский журнал. 2004;12(10):573–7. [Zakharov VV, Yakhno NN. Syndrome of moderate cognitive frustration at advanced age: diagnostics and treatment. Russkii meditsinskii zhurnal. 2004;12(10):573–7. (In Russ.)]
16. Слободин ТН, Горева АВ. Когнитивный резерв: причины снижения и защитный механизмы. Международный неврологический журнал. 2012;49(3):45–51. [Slobodin TN, Goreva AV. Cognitive reserve: reasons of decrease and protective mechanisms. International neurological journal. 2012;49(3):45–51. (In Russ.)]
17. Fernandes MA, Craik F, Bialystok E, et al. Effects of bilingualism, aging, and semantic relatedness on memory under divided attention. Canadian Journal of Experimental Psychology. Can J Exp Psychol. 2007;61(2):128–41.
18. Камчатнов ПР. Когнитивный резерв, когнитивные нарушения и возможности их медикаментозной коррекции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2014;114(3):87-91. [Kamchatnov PR. Cognitive reserve, cognitive impairment and possibilities of their pharmacological correction. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;114(3):87–91. (In Russ.)]
19. Dhawan J, Benveniste H, Luo Z, et al. A new look at glutamate and ischemia: NMDA agonist improves long-term functional outcome in a rat model of stroke. Future Neurol. 2011;6(6):823–34. DOI: http://dx.doi.org/10.2217/fnl.11.55.
20. Гусев ЕИ, Камчатнов ПР. Пластичность головного мозга в норме и патологии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2004;104(2):73–80. [Gusev EI, Kamchatnov PR. Plasticity of a brain in norm and pathology. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2004;104(2):73–80. (In Russ.)]
21. Frisoni GB, Galuzzi S, Bresciani L, et al. Mild cognitive impairment with subcortical vascular
22. futures. Clinical characteristics and outcome. J Neurology. 2002;249(10):1423–32. 22. Silvestrini M, Pasqualetti P, Baruffaldi R, et al. Cerebrovascular reactivity and cognitive decline in patients with Alzheimer’s disease. Stroke. 2006;37(4):1010–5. Epub 2006 Feb 23. DOI: http://dx.doi.org/10.1161/01.STR.0000206439.62025.97.
23. Mendoca AD, Ribeiro F, Guerreiro M,et al. Clinical significance of subcortical vascular disease in patients with mild cognitive impairment. Eur J Neurol. 2005;12(2):125–30. DOI: http://dx.doi.org/10.1111/j.1468-1331.2004.00892.x.
24. Song IU, Kim JS, Kim YI. Clinical significance of silent cerebral infarctions in patiens with Alzheimer’s disease. Cogn Behav Neurol.. 2007;20(2):99–106.
25. Kalaria R. Similarities between Alzheimer’s disease and vascular dementia. J Neurol Sci. 2002;(203–204):29–34.
26. Dhat NR. Linking cardiometabolic disorders to sporadic Alzheimer’s disease: a perspective
27. on potential mechanism and mediators. J Neurochemistry. 2010;115(3):551–62. DOI: http://dx.doi.org/10.1111/j.1471-4159.2010.06978.x.
28. Левин ОС. Когнитивные нарушения в практике невролога. Москва; 2006. [Levin OS. Kognitivnye narusheniya v praktike nevrologa [Cognitive violations in practice of the neurologist]. Moscow; 2006.]
29. Чердак МА, Парфенов ВА. Когнитивные расстройства у пациентов, перенесших ишемический инсульт. Неврологический журнал. 2011;16(6):37–44. [Cherdak MA, Parfenov VA. The cognitive impairments in patients after ischemic stroke. Nevrologicheskii zhurnal. 2011;16(6):37–44. (In Russ.)]
30. Palmer K, Wang H-X, Backman L, et al. Differential evolution of cognitive impairment in nondemented older persons. Am J Psychiatry. 2002;159(3):436–42. DOI: http://dx.doi.org/10.1176/appi.ajp.159.3.436.
31. Пизова НВ. Амбулаторное ведение больных после тяжелого инсульта с деменцией. Неврология, нейропсихиатрия, психосоматика. 2013;(4):78–83. [Pizova NV. Outpatient management after severe stroke with dementia. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2013;(4):78–83. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2013-2460.
32. Парфенов ВА. Артериальная гипертония и инсульт. Неврологический журнал. 2001;(6):4–7. [Parfenov VA. Arterial hypertension and stroke. Nevrologicheskii zhurnal. 2001;(6):4–7. (In Russ.)]
33. Яхно НН, Парфенов ВА, Климов ЛВ. Когнитивные расстройства при ишемическом инсульте в каротидной системе. I Российский международный конгресс: цереброваскулярная патология и инсульт. Журнал неврологии и психиатрии им. С.С. Корсакова. Приложение Инсульт. 2003;103(9s):171. [Yakhno NN, Parfenov VA, Klimov LV. Cognitive frustration at an ischemic stroke in carotid system. I Russian international congress: tserebrovaskulyarny pathology and stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. Issue Stroke. 2003;103(9s):171. (In Russ.)]
34. Reed BR, Marchant NL, Jagust WJ, et al. Coronary risk correlates with cerebral amyloid deposition. Neurobiol Aging. 2012;33(9):1979–87. DOI: http://dx.doi.org/10.1016/j.neurobiolaging.2011.10.002.
35. Glogzik L, Rusinek H, Brys M, et al. Framingham cardiovascular risk profile correlates with impaired hippocampal and cortical vasoreactivity to hypercapnia. J Cerebral Blood Flow Metabolism. 2011;31(2):671–9. DOI: 10.1038/jcbfm.2010.145. Epub 2010 Sep 15.
36. Eckroth-Bucher M, Siberski J. Preserving cognition through an integrated cognitive stimulation and training program. Am J Alzheimers Dis Other Dement. 2009;24(3):234–45. DOI: http://dx.doi.org/10.1177/1533317509332624.
37. Willis S, Tennstedt S, Marsiske M, et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA. 2006;296(25):2805–14. DOI: http://dx.doi.org/10.1001/jama.296.23.2805.
38. Biffi A, Halpin A, Towfighi A. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology. 2010;75(8):693–8. DOI: http://dx.doi.org/10.1212/WNL.0b013e3181eee40f.
39. Thoonsen H, Richard E, Bentham P. Aspirin in Alzheimer's disease: increased risk of intracerebral hemorrhage: cause for concern? Stroke. 2010;41(11):2690–2. DOI: http://dx.doi.org/10.1161/STROKEAHA.109.576975.
40. Winblad B, Carfagna N, Bonura L, et al. Nicergoline in dementia. A review of its pharmacological properties and therapeutical potential. CNS Drugs. 2000;(14):267–87. DOI: http://dx.doi.org/10.2165/00023210-200014040-00003.
41. Fariello RG. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art. Funct Neurol. 1997;12(3–4):221–5.
42. Winblad B, Fioravanti M, Dolezal T, et al. Therapeutic use of nicergoline. Clin Drug Investig. 2008;28(9):533–52. DOI: http://dx.doi.org/10.2165/00044011-200828090-00001.
43. Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev. 2001;(4):CD003159.
44. Pantoni L. Treatment of vascular dementia: evidence from trials with noncholinergic drugs. J Neurol Sci. 2004;226(1–2):67–70.
45. Li XF, Hu CL. Effect of nicergoline on cognition function of patients with cerebral infarction. Chinese J Clinical Rehabilitation. 2005;9:186–7.
46. Hock C. Biochemical aspects of dementia. Dialogues Clin Neurosci. 2003;5(1):27–34.
47. Ogawa N, Asanuma M, Hirata H, et al. Cholinergic deficits in aged rat brain are corrected with nicergoline. Arch Gerontol Geriatr. 1993;16(2):103–10. DOI: http://dx.doi.org/10.1016/0167-4943(93)90001-X.
48. Бурчинский СГ. Вазотропная фармакотерапия: новые аспекты. Журнал практика лiкаря. 2001;6:57–60. [Burchinskii SG. Vazotropny pharmacotherapy: new aspects. Zhurnal praktika likarya. 2001;6:57–60. (In Russ.)]
49. Winblad B, Bonura ML, Rossini BM, et al. Nicergoline in the treatment of mild-to-moderate Alzheimer’s disease. A European multicentre trial. Clin Drug Investig. 2001;(21):621–32. DOI: http://dx.doi.org/10.2165/00044011-200121090-00004.
50. Crook TH. Nicergoline: Parallel evolution of clinical trial methodology and drug development in dementia. Dement Geriat Cogn Dis. 1997;8(1):22–6. DOI: http://dx.doi.org/10.1159/000106667.
51. Saletu B, Paulus E, Linzmayer L, et al. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a doubleblind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacol (Berl). 1995;117(4):385–95. DOI: http://dx.doi.org/10.1007/BF02246209.
52. Saletu B, Anderer P, Semlitsch HV. Relations between symptomatology and brain function in dementias: Double-blind, placebocontrolled, clinical and EEG/ERP mapping studies with nicergoline. Dement Geriat Cogn Dis. 1997;8(1):12–21. DOI: http://dx.doi.org/10.1159/000106666.
53. Baskys A, Hou AC. Vascular dementia: Pharmacological treatment approaches and perspectives.
54. Clin Intervent Aging. 2007;2(3):327–35.
55. Nappi G, Bono G, Merlo G, et al. Longterm nicergoline treatment of mild to moderate senile dementia. Results of a multicentre, double-blind, placebo-controlled study. Clin Drug Invest. 1997;(13):308–16. DOI: http://dx.doi.org/10.2165/00044011-199713060-00003.
56. Bes A, Orgogozo J-M, Poncet M, et al. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol. 1999;6(3):313–22. DOI: http://dx.doi.org/10.1046/j.1468-1331.1999.630313.x.
57. Руденко ГМ, Музыченко АП. Результаты клинического изучения препарата сермион (анализ данных фармакологического комитета). Москва; 1987. 31 с. [Rudenko GM, Muzychenko AP. Rezul'taty klinicheskogo izucheniya preparata sermion (analiz dannykh farmakologicheskogo komiteta) [Results of clinical studying of a preparation sermion (analysis of data of pharmacological committee)]. Moscow; 1987. 31 p.]
58. Kamizaki Y. Sermion (nicergoline) therapy for sleeplessness associated with cerebrovascular disease. Pharma Medica. 2004;22(3):169–75.
59. Katsumata T, Katayama Y. Treatment by medicine which improves cerebral circulation and metabolism. Nippon Rinsho. 2006;64 Suppl 8:81–4.
Рецензия
Для цитирования:
Дайникова Е, Пизова Н. Когнитивный резерв и когнитивные нарушения: лекарственные и нелекарственные методы коррекции. Неврология, нейропсихиатрия, психосоматика. 2014;6(2S):62-68. https://doi.org/10.14412/2074-2711-2014-2S-62-68
For citation:
Dainikova E, Pizova N. Cognitive reserve and cognitive impairments: drug and nondrug treatments. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6(2S):62-68. (In Russ.) https://doi.org/10.14412/2074-2711-2014-2S-62-68
Просмотров:
1126
Послать статью по эл. почте 